2026 - Introduced
Missouri H.B. 2372
  • Requires insurance to cover non-opioid medications for enrollees at elevated risk of opioid misuse without requiring prior opioid use, denying coverage in favor of opioids, or imposing higher cost-sharing.
State Regulated Commercial Parity
Read House Bill
2026 - Introduced
Missouri S.B. 902/S.B. 1340/S.B. 1449/S.B. 841/H.B. 2642/S.B. 878/ S.B. 1350
  • Requires Missouri commercial plans to cover non-opioid medications for acute pain without denying coverage in favor of opioids, mandating prior opioid use, or imposing utilization controls, such as higher cost-sharing or step therapy, or prior authorization when prescribed.
State Employee Health Plan ParityState Regulated Commercial Parity
Read S.B. 902Read S.B. 1350Read S.B. 1449Read S.B. 841Read H.B. 2642Read S.B. 878Read S.B. 1350
2025 - Introduced
Missouri S.B.158/H.B. 804
  • For enrollees with an increased risk of opioid abuse, prohibits health insurers from: (1) denying coverage for non-opioid prescription drugs in favor of opioid drugs; (2) requiring an enrollee try an opioid prescription drug prior to approving the use of a non-opioid prescription drug; or (3) requiring a higher cost-sharing for non-opioid prescription drugs.
State Regulated Commercial Parity
Read Senate BillRead House Bill
2025 - Introduced
Montana H.B. 774
  • Prohibits Medicaid and health insurers from denying coverage of a non-opioid in favor of an opioid and requires that in establishing a drug formulary, the Montana Department of Public Health and Human Services must ensure a non-opioid is not disadvantaged or discouraged as compared to coverage of an opioid.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2025 - Introduced
Nevada S.B. 377
  • Requires health insurers and Medicaid cover at least one alternative to an opioid and prohibits insurers from requiring prior authorization or other restrictive requirements for an alternative to an opioid compared to requirements established for an opioid.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2025 - Introduced
New Hampshire H.B.241
  • Requires health insurance plans to cover a broad range of non-opioid pain management services, treat non-opioid therapies no less favorable than opioids, and provide educational materials to policyholders and coordinated care.
State Regulated Commercial Parity
Read Bill
2024 - Introduced
New Jersey A4682
  • Prohibits health insurers, Medicaid and School Employees’ Health Benefits from denying coverage of non-opioid prescription drugs in favor of opioid prescription drugs. Further, formularies are prohibited from disincentivizing the use of non-opioids with respect to coverage or cost-sharing.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2026 - Introduced
New York Assembly Bill A1921A
  • Prohibits health insurers and state-regulated plans from disadvantaging clinically appropriate non-opioid pain treatments, including by imposing stricter prior authorization, step therapy, or less favorable tier placement, compared to opioid drugs used for pain.
State Regulated Commercial Parity
Read Bill
2026 - Introduced
Oklahoma S.B. 1563
  • Requires the state Medicaid program and regulated health plans cover FDA-approved non-opioid pain treatments without requiring patients to try opioids first and without less favorable coverage or higher cost-sharing than opioid treatments.
  • Prohibits Medicaid formularies and carrier utilization controls from disadvantaging clinically appropriate non-opioid pain treatments, such as through prior authorization or step therapy, compared to opioids.
  • Directs the state to leverage grants and opioid settlement funds to support education on non-opioid options.
Medicaid ParityState Regulated Commercial Parity
Read Senate Bill
2025 - Introduced
Oregon S.B.598
  • Requires health insurers and Medicaid establish parity for opioids and non-opioid treatments.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2026 - Introduced
South Dakota H.B. 1085
  • Prohibits South Dakota insurers from denying coverage of a prescribed non-opioid medication in favor of an opioid.
  • Bars insurers from imposing stricter utilization controls or higher cost-sharing for non-opioid drugs than for clinically appropriate opioid or narcotic drugs.
State Regulated Commercial Parity
Read House Bill
2025 - Introduced
South Dakota H.B.1137
  • Ensures FDA-approved non-opioid drugs are not disadvantaged or discouraged with respect to coverage of an opioid on the state preferred drug list.
Medicaid ParityState Regulated Commercial Parity
Read Bill